Cell No. : Cell Name
RCB0701 : 143B/TK^(-)neo^(R)
update : 2021/05/20
|
| Comment | v-Ki-ras transformant TE85 cell line. HAT sensitive, neo resistant. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Sugimoto, Yoshikazu
|
| Originator |
Croce, C.
|
| Year of deposit |
1991
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Unknown
|
| Tissue |
osteosarcoma
|
| Classification |
transformed
|
| Recombinant |
recombinant
|
| Exogene |
v-Ki-ras
|
| History |
Dr. Perira-Smith M. Olivia
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
| Cellosaurus(Expasy) |
CVCL_9W36
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
MEM + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
46-125(50) : /48(11),49(13),50(10),51(4),53(2)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
12
|
| User's Publication |
|
11888
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Ideta H, Kamanaka T, Sobajima A, Takizawa T, Tanaka M, Aoki K, Uemura T, Kato H, Haniu H, Saito N.
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
BMC Cancer
2020
20(1):25.
PubMed ID: 31914969
|
|
11888
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Ideta H, Kamanaka T, Sobajima A, Takizawa T, Tanaka M, Aoki K, Uemura T, Kato H, Haniu H, Saito N.
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
BMC Cancer
2020
20(1):25.
PubMed ID: 31914969
|
|
13141
Oka N, Komuro A, Amano H, Dash S, Honda M, Ota K, Nishimura S, Ueda T, Akagi M, Okada H.
Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.
Pharmacol Res Perspect
2020
PubMed ID: 32725721
|
|
13306
Ando T, Ichikawa J, Fujimaki T, Taniguchi N, Takayama Y, Haro H.
Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis.
Cancers (Basel)
2020
PubMed ID: 33114161
|
|
11978
Asano N, Takeshima H, Yamashita S, Takamatsu H, Hattori N, Kubo T, Yoshida A, Kobayashi E, Nakayama R, Matsumoto M, Nakamura M, Ichikawa H, Kawai A, Kondo T, Ushijima T.
Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas.
Sci Rep
2019
PubMed ID: 31889115
|
|
9465
Tomohiko Tokunaga, Takashi Ando, Miki Suzuki-Karasaki, Tomohisa Ito, Asuka Onoe-Takahashi, Toyoko Ochiai, Masayoshi Soma , Yoshihiro Suzuki-Karasaki
Plasma-stimulated Medium Kills TRAIL-resistant Human Malignant Cells by Promoting Caspase-Independent Cell Death via Membrane Potential and Calcium Dynamics Modulation
Int J Oncol
2018
52(3):697-708
PubMed ID: 29393427
|
|
14766
Wada KI, Hosokawa K, Ito Y, Maeda M.
Quantitative control of mitochondria transfer between live single cells using a microfluidic device
Biol Open
2017
6(12):1960-1965
PubMed ID: 29092814
|
|
10919
Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcoma
Integr Mol Med
2016
3: 755-760
|
|
8566
Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K.
Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.
Cancer Sci.
2009
100:1227-33
PubMed ID: 19486338
|
|
9072
M Saijo, T Suzutani, K Mizuta, I Kurane, S Morikawa
Characterization and Susceptibility to Antiviral Agents of Herpes Simplex Virus Type 1 Containing a Unique Thymidine Kinase Gene With an Amber Codon Between the First and the Second Initiation Codons
Arch Virol
2008
153 (2), 303-14
PubMed ID: 18066636
|
|
9041
Tatsuo Suzutani, Ken Ishioka, Erik De Clercq, Kei Ishibashi, Hisatoshi Kaneko, Toshihiko Kira, Koh-Ichi Hashimoto, Masahiro Ogasawara, Katsuki Ohtani, Nobutaka Wakamiya, Masayuki Saijo
Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir
Antimicrob Agents Chemother
2003
47 (5), 1707-13
PubMed ID: 12709344
|
|
9034
Masayuki Saijo, Tatsuo Suzutani, Erik De Clercq, Masahiro Niikura, Akihiko Maeda, Shigeru Morikawa, Ichiro Kurane
Genotypic and Phenotypic Characterization of the Thymidine Kinase of ACV-resistant HSV-1 Derived From an Acyclovir-Sensitive Herpes Simplex Virus Type 1 Strain
Antiviral Res
2002
56 (3), 253-62
PubMed ID: 12406508
|
Back
Top
CELL BANK Website
